Neoleukin-2 enhances anti-tumour immunity downstream of peptide vaccination targeted by an anti-MHC class II VHH.
Animals
Antigens, Neoplasm
/ immunology
Autoantigens
/ immunology
CD8-Positive T-Lymphocytes
/ immunology
Camelids, New World
/ immunology
Cancer Vaccines
/ administration & dosage
Cell Line, Tumor
Drug Synergism
Histocompatibility Antigens Class II
/ immunology
Interleukin-2
/ administration & dosage
Melanoma
/ drug therapy
Mice
Peptides
/ administration & dosage
Recombinant Proteins
/ administration & dosage
Single-Domain Antibodies
/ metabolism
Vaccines, Subunit
Xenograft Model Antitumor Assays
VHH
alpaca nanobodies
cancer immunology
cancer vaccines
cytokines
neoantigens
Journal
Open biology
ISSN: 2046-2441
Titre abrégé: Open Biol
Pays: England
ID NLM: 101580419
Informations de publication
Date de publication:
02 2020
02 2020
Historique:
entrez:
6
2
2020
pubmed:
6
2
2020
medline:
23
10
2020
Statut:
ppublish
Résumé
Cancer-specific mutations can lead to peptides of unique sequence presented on MHC class I to CD8 T cells. These neoantigens can be potent tumour-rejection antigens, appear to be the driving force behind responsiveness to anti-CTLA-4 and anti-PD1/L1-based therapies and have been used to develop personalized vaccines. The platform for delivering neoantigen-based vaccines has varied, and further optimization of both platform and adjuvant will be necessary to achieve scalable vaccine products that are therapeutically effective at a reasonable cost. Here, we developed a platform for testing potential CD8 T cell tumour vaccine candidates. We used a high-affinity alpaca-derived VHH against MHC class II to deliver peptides to professional antigen-presenting cells. We show
Identifiants
pubmed: 32019478
doi: 10.1098/rsob.190235
pmc: PMC7058936
doi:
Substances chimiques
Antigens, Neoplasm
0
Autoantigens
0
Cancer Vaccines
0
Histocompatibility Antigens Class II
0
Interleukin-2
0
Peptides
0
Recombinant Proteins
0
Single-Domain Antibodies
0
Vaccines, Subunit
0
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, U.S. Gov't, Non-P.H.S.
Langues
eng
Sous-ensembles de citation
IM
Pagination
190235Subventions
Organisme : NIDDK NIH HHS
ID : K08 DK114563
Pays : United States
Organisme : NIAID NIH HHS
ID : P01 AI098681
Pays : United States
Références
J Immunol. 2007 Oct 15;179(8):5033-40
pubmed: 17911588
J Exp Med. 2017 Aug 7;214(8):2243-2255
pubmed: 28666979
Nature. 2017 Jul 13;547(7662):217-221
pubmed: 28678778
Cancer Immunol Res. 2013 Jul;1(1):11-5
pubmed: 24777245
J Nucl Med. 2017 Jun;58(6):1003-1008
pubmed: 28209904
Nature. 1991 Apr 4;350(6317):423-6
pubmed: 1901381
Clin Cancer Res. 2008 Jan 1;14(1):169-77
pubmed: 18172268
ACS Cent Sci. 2015 Jun 24;1(3):142-147
pubmed: 26955657
Nat Med. 2016 Dec;22(12):1402-1410
pubmed: 27775706
Clin Cancer Res. 2008 Jan 1;14(1):178-87
pubmed: 18172269
Nat Rev Immunol. 2018 Mar;18(3):168-182
pubmed: 29226910
Science. 2015 Oct 9;350(6257):207-211
pubmed: 26359337
Nat Med. 2004 Sep;10(9):909-15
pubmed: 15340416
Cell. 1994 Jan 14;76(1):17-27
pubmed: 8287475
Nature. 2019 Jan;565(7738):234-239
pubmed: 30568305
Annu Rev Immunol. 2018 Apr 26;36:695-715
pubmed: 29490163
Proc Natl Acad Sci U S A. 2019 Jul 9;116(28):14181-14190
pubmed: 31068469
Proc Natl Acad Sci U S A. 2016 Nov 8;113(45):E7039-E7048
pubmed: 27791170
J Immunol. 2013 Jun 15;190(12):6230-8
pubmed: 23677467
Nature. 2019 Jan;565(7738):186-191
pubmed: 30626941
Cancer Immunol Res. 2018 Jul;6(7):870-880
pubmed: 29792298
Nat Commun. 2017 May 12;8:15373
pubmed: 28497796
Proc Natl Acad Sci U S A. 2019 Apr 16;116(16):7624-7631
pubmed: 30936321
Nature. 2017 Jul 13;547(7662):222-226
pubmed: 28678784
Cancer Immunol Res. 2018 Apr;6(4):389-401
pubmed: 29459478
Proc Natl Acad Sci U S A. 2018 Apr 10;115(15):3912-3917
pubmed: 29581255
Cancer Immunol Res. 2013 Aug;1(2):99-111
pubmed: 24459675
Science. 2008 Nov 14;322(5904):1097-100
pubmed: 19008445
Chem Sci. 2017 Aug 1;8(8):5591-5597
pubmed: 28970938
Nature. 2012 Mar 25;484(7395):529-33
pubmed: 22446627
Gastroenterology. 2019 May;156(7):2056-2072
pubmed: 30660727
Annu Rev Cell Dev Biol. 2018 Oct 6;34:163-188
pubmed: 30110557
Nature. 2019 Jan;565(7738):240-245
pubmed: 30568303
Nat Commun. 2017 Sep 21;8(1):647
pubmed: 28935898
Gastroenterology. 2018 Jul;155(1):11-14
pubmed: 29885301
Nat Rev Cancer. 2004 Jan;4(1):11-22
pubmed: 14708024
Fly (Austin). 2012 Apr-Jun;6(2):80-92
pubmed: 22728672
Hematol Oncol Clin North Am. 2014 Jun;28(3):559-69
pubmed: 24880947
Cancer Immunol Res. 2018 Dec;6(12):1524-1536
pubmed: 30352798
J Clin Oncol. 1991 Apr;9(4):694-704
pubmed: 2066765
Nature. 2006 Nov 2;444(7115):115-8
pubmed: 17051151
PLoS One. 2017 Dec 4;12(12):e0189068
pubmed: 29200433
J Mol Biol. 1995 Apr 14;247(5):979-94
pubmed: 7723044
Oncoimmunology. 2018 Sep 6;7(12):e1511506
pubmed: 30524907
Nat Rev Immunol. 2012 Feb 17;12(3):180-90
pubmed: 22343569
J Immunol. 2016 Dec 15;197(12):4838-4847
pubmed: 27821668
Cancer Cell. 2003 Dec;4(6):437-50
pubmed: 14706336